Press coverage about Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) has been trending somewhat positive on Thursday, according to Accern. The research firm rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Trillium Therapeutics earned a coverage optimism score of 0.20 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 45.948319691654 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
A number of research analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of Trillium Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a research note on Thursday, November 23rd. ValuEngine upgraded shares of Trillium Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, December 1st. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Trillium Therapeutics in a research note on Thursday, December 14th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. Trillium Therapeutics presently has a consensus rating of “Hold” and an average price target of $12.25.
Trillium Therapeutics (NASDAQ:TRIL) traded up $0.45 during trading hours on Thursday, hitting $8.15. 116,841 shares of the stock were exchanged, compared to its average volume of 86,168. Trillium Therapeutics has a 52 week low of $4.15 and a 52 week high of $13.30. The company has a quick ratio of 6.33, a current ratio of 6.33 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $83.12, a PE ratio of -3.17 and a beta of 13.72.
ILLEGAL ACTIVITY WARNING: “Trillium Therapeutics (NASDAQ:TRIL) Getting Somewhat Positive Press Coverage, Analysis Finds” was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://stocknewstimes.com/2018/01/11/trillium-therapeutics-tril-getting-somewhat-positive-press-coverage-study-shows.html.
Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The companys lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy.
Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.